Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Eli Lilly is now selling Mounjaro GLP-1 weight loss drugs in India. Rival Novo Nordisk began Indian Wegovy sales in June.

NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's ...

Cantor Fitzgerald analyst Carter Gould lowered the firm’s price target on Eli Lilly (LLY) to $825 from $975 and keeps an ...

Eli Lilly (LLY) stock recovers as company executives seize a rare buying opportunity to make a series of insider purchases ...

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

Although new medicines can help you lose weight faster and healthier than ever, a new psychology is needed to keep your ...

Oregon Health & Science University said a trained AI program can detect cancer of a larynx by picking up the distinct ...

The Clean Label Project tested store-bought coffee and found it is mostly free of harmful levels of toxins and contaminants, ...